Loading…
ERYTECH and Catalent have entered a long-term supply agreement for the clinical and commercial supply of eryaspase (GRASPA).
Catalent has acquired ERYTECH's U.S. cell therapy manufacturing facility for $44.5 million. The companies also entered a long-term supply agreement for eryaspase (GRASPA).